Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.
Trevi Therapeutics, Inc. reports news on its clinical-stage biopharmaceutical development of Haduvio, an oral extended-release formulation of nalbuphine, for chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. Company updates commonly cover clinical trial results and plans, FDA interactions, medical-conference presentations, intellectual property, and the investigational status of Haduvio.
Trevi also reports financing and corporate updates tied to its development strategy, including common stock offerings, quarterly financial results, cash runway commentary, and participation in healthcare investor events.
Trevi Therapeutics (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, has announced it will report its second quarter 2024 financial results and provide a corporate update on August 8, 2024. The company is developing Haduvio™ (oral nalbuphine ER) for treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). A conference call and live audio webcast will be held at 4:30 p.m. ET on the same day.
Interested parties can join the call by dialing (877) 870 4263 (domestic) or (412) 317 0790 (international) and asking to join the Trevi Therapeutics call. A live audio webcast will be available on the company's website, with an archived replay accessible for 30 days following the event.
Trevi Therapeutics (Nasdaq: TRVI), specializing in therapies for chronic cough, announced their participation in key investor and healthcare events in July and August 2024. Senior management, including CEO Jennifer Good and CFO Lisa Delfini, will represent the company at the Leerink Partners Therapeutics Forum on July 9-10 in Boston, MA. Additionally, two abstracts from Trevi's ongoing clinical trials, CORAL (Phase 2b) and RIVER (Phase 2a), have been accepted for presentation at the 13th London International Cough Symposium on July 18-19, 2024. The symposium will discuss advancements in chronic cough research and treatment. CEO Jennifer Good will also represent Trevi at Oppenheimer's Biotech in the Berkshires on August 5-7 in Lenox, MA, and the Stifel 2024 Biotech Summer Summit on August 12-14 in Newport, RI.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company (Nasdaq: TRVI), will participate in upcoming investor, business development, and medical conferences in May and June. The company is focused on developing Haduvio™ for chronic cough in idiopathic pulmonary fibrosis and refractory chronic cough. Senior management will attend various events, including the Citizens JMP Life Sciences Conference, ATS 2024 International Conference, 2024 BIO International Convention, and Oppenheimer's 2024 Montauk Life Sciences Summit.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) reported Q1 2024 financial results and business updates, reaffirming guidance for Phase 2a RIVER trial and HAP Study. Topline data for both trials expected in 2024. IND cleared for Phase 1b trial. Key business updates include progress in clinical trials, with Phase 2a RIVER trial and Phase 2b CORAL trial enrollment ongoing. The company ended Q1 2024 with $72.8 million in cash. Financially, R&D expenses increased to $8.8 million, G&A expenses were $3.1 million, with a net loss of $10.9 million. Conference call/webcast and upcoming meetings announced for investor participation.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) will host a conference call and webcast on May 7, 2024, to discuss the corporate update and financial results for the first quarter of 2024. The company is developing Haduvio™ for chronic cough in IPF and RCC. Investors can participate via phone or webcast.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.